发明名称 Therapeutic combinations for treating Johne's disease
摘要 In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.
申请公布号 US9616121(B2) 申请公布日期 2017.04.11
申请号 US201314405384 申请日期 2013.06.04
申请人 Center for Digestive Diseases 发明人 Agrawal Gaurav
分类号 A61K39/395;A61K31/133;A61K31/4164;A61K31/435;A61K33/00;A61K31/7048;A61K31/498;A61K31/496;A61K39/40;A61K39/00;A23G3/36;A23G4/06;A23C9/123;A23G9/32 主分类号 A61K39/395
代理机构 Greer, Burns & Crain, Ltd. 代理人 Greer, Burns & Crain, Ltd. ;Einhorn Gregory P.
主权项 1. A therapeutic combination for treating or ameliorating Johne's disease, comprising: (1) an anti-TNFα composition or drug, or a composition or a drug capable of down-modulating or down-regulating a TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT, or the medical use of oxygen at a level higher than atmospheric pressure; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition, drug or therapy.
地址 New South Wales AU